Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
sintilimab + regorafenib
- Development stage
- Phase 2
- Lead developer
- Innovent Biologics
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
Sintilimab + regorafenib is a combination therapy consisting of sintilimab, a monoclonal antibody targeting the programmed cell death protein 1 (PD-1), and regorafenib, an oral small molecule multikinase inhibitor. Sintilimab acts as an immune checkpoint inhibitor by blocking PD-1 on T cells, thereby enhancing antitumor immune responses. Regorafenib inhibits multiple kinases involved in tumor angiogenesis (such as VEGFR), oncogenesis, and the tumor microenvironment. This combination has been investigated primarily for advanced or metastatic cancers that are refractory to standard therapies, including microsatellite stable metastatic colorectal cancer (MSS mCRC) and hepatocellular carcinoma (HCC). Clinical studies have shown that this regimen can improve overall survival and response rates compared to monotherapy with either agent alone, with a manageable safety profile[1][2][3][8].
- Brand names
- Tyvyt (sintilimab)Stivarga (regorafenib)
- Other names
- rego-sintilimab
02
Targets
BRAF (B-Raf proto-oncogene, serine/threonine kinase)FGFR1 (Fibroblast growth factor receptor 1)KIT (c-KIT proto-oncogene receptor tyrosine kinase)PDGFRB (Platelet-derived growth factor receptor beta)PDCD1 (Programmed cell death protein 1 receptor)RAF1 (c-Raf-1 (Y340D/Y341D))RET (Rearranged during transfection receptor tyrosine kinase)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR2 (Vascular endothelial growth factor receptor 2)VEGFR4 (Vascular endothelial growth factor Receptor-3)
Beyond the preview
Go deeper on sintilimab + regorafenib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on sintilimab + regorafenib.